The European Commission authorized Pfizer and BioNTech’s updated COVID-19 vaccine for the 2026-2027 season on July 29, targeting the XFG variant with data showing a strong immune response against contemporary circulating and emerging lineages.
The vaccine is approved for individuals 6 months of age and older across all 27 European Union Member States, plus Iceland, Liechtenstein, and Norway. The authorization follows a recommendation from the European Medicines Agency’s Emergency Task Force, which stated that “the evidence suggests that targeting XFG would provide the best protection against COVID-19.”
Pfizer and BioNTech have already begun manufacturing the monovalent XFG-adapted vaccine “at risk” to ensure supply readiness ahead of the respiratory disease season when demand for COVID-19 vaccination typically increases. The companies noted that more than five billion doses of their COVID-19 vaccines have been distributed globally since the pandemic began.
The authorization is based on cumulative evidence including clinical, non-clinical, and real-world data demonstrating the vaccine’s safety and efficacy. The vaccine generated strong immune responses against multiple SARS-CoV-2 lineages, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other contemporary variants. The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval on July 23, 2026.
The XFG variant was designated a variant under monitoring by the World Health Organization in June 2025, with increasing proportions globally. The U.S. FDA’s advisory panel recommended in May 2026 that COVID-19 vaccines for the 2026-2027 season target this variant. All major vaccine manufacturers, including Pfizer, Moderna, and Sanofi, indicated they were prepared to produce XFG-adapted vaccines for the upcoming season.
Shipping of the updated vaccine will begin soon to ensure rapid access across Europe. EU Member States and Norway will receive supplies either through the European Commission contract or according to individual country government policies. The authorization specifically targets the XFG variant as the preferred approach for the 2026-2027 immunization campaign.
Sources
- Pfizer — European Commission authorization announcement, vaccine data, manufacturing status, distribution history
- Clinical Trial Vanguard — EU authorization details, cross-reactive immunity data across JN.1 lineage variants
- Yahoo Finance Healthcare — European Commission authorization, vaccine efficacy profile
- American Pharmaceutical Review — Marketing authorization details, age eligibility
- FDA — May 2026 advisory panel recommendation for XFG variant targeting
- WHO — XFG variant designation as variant under monitoring, June 2025
- MedPage Today — FDA panel vote and manufacturer preparedness statement
